Master Alliance Provisions Guide (MAPGuide)

AXA Prime Impact Master Fund – Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement

  • Equitable Access | Affordable pricing

Provision Language

<p class=”p1“><span style=”text–decoration: underline;”><strong>4. Program–Related Investment Requirements<span class=”Apple–converted–space“> span>strong>span>p>
<p class=”p1“>In consideration of the Investor making, or having made, the Investment on the terms and conditions stated herein and in the Investment Documents, and for other good and valuable consideration, the undersigned hereby agree as follows:<span class=”Apple–converted–space“> span>p>
<p>[&#8230;]p>
<p class=”p1“><strong>(b) Global Access Commitments<span class=”Apple–converted–space“> span>strong>p>
<p class=”p1“>(i) Beginning on the date of this Global Health Agreement, the Company shall conduct the following activities to advance the Global Health Objectives during the Term:<span class=”Apple–converted–space“> span>p>
<p>[&#8230;]p>
<p>(2) The Company shall make Program Products available to non–profit organizations and public–sector purchasers in Target Countries (“<em><strong>Global Health Purchasersstrong>em>”) at a price of no more than 30% above the Company’s COGS, in Low-Income Countries and in Low–Middle–Income Countries, if approved by the Global Access Committee (as defined below); provided, however, that any non–profit organization and public–sector purchaser located in Brazil, India, South Africa and Mexico shall need to be approved by the Global Access Committee before qualifying as a “Global Health Purchaser” within the terms of this Global Health Agreement.p>

Download Full Agreement